JPRN-jRCTc030190260招募中1 期
A clinical study on the safety of the preventive gdT cell therapy against cancer.
Goto Shigenori0 个研究点目标入组 650 人开始时间: 2020年3月16日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •(1)Have risk factors for cancer and desire for receiving the preemptive immune-cell therapy.
- •(2)Be > 18 of age when obtaining the informed consent.
- •(3)Provide written informed consent.
- •(4)Be determined to be appropriate by the doctor in charge.
排除标准
- •(1)Be diagnosed with cancer.
- •(2)Desire to receive the immune-cell therapy for the treatment of any allergic disease.
- •(3)Be HIV or HTLV-1 positive.
- •(4)Be an allotransplant recipient.
- •(5)Have a history or sign of interstitial pneumonia.
- •(6)Have an active autoimmune disease.
- •(7)Be a female who is pregnant, nursing, or of childbearing potential.
- •(8)A subject 70 years of age and above must be carefully considered for the risk of an autoimmune disease to enroll in this study.
- •(9)Be determined to be inappropriate by the doctor in charge.
研究者
相似试验
招募中
1 期
Safety evaluation of the preemptive immune-cell therapy against cancer.JPRN-jRCTc030190259Goto Shigenori650
招募中
1 期
Safety evaluation of the preemptive immune-cell therapy against cancer.JPRN-jRCTc030230349Goto Shigenori650
招募中
1 期
Safety evaluation of the preemptive immune-cell therapy against cancer.JPRN-jRCTc030190261Goto Shigenori650
尚未招募
2 期
A study of the effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) for patients with esophageal cancer who receive DCF therapy.esophageal cancerJPRN-UMIN000015561Osaka University School of Medicine Gastroenterological Surgery23
尚未招募
2 期
Trial of prophylactic GCSF (white cell growth factor) use to prevent low white cell counts in people re-exposed to clozapineeutropeniaAdverse drug reactionNeutropeniaBlood - Other blood disordersMental Health - SchizophreniaSchizophreniaACTRN12618001830280niversity of Queensland20